Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer
批准号:
10223238
负责人:
Shehzad Basaria
金额:
$64.36万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-05-08 至 2025-04-30
关键词:
AffectAgeBody CompositionCancer PatientCancer SurvivorCardiovascular systemChemotherapy and/or radiationClinicClinicalCranial IrradiationDataDecreased LibidoDiagnosisDisease remissionDouble-Blind MethodErectile dysfunctionExhibitsFatigueFatty acid glycerol estersGoalsHigh PrevalenceIndividualInjectionsLongevityMalignant NeoplasmsMeasurementMoodsOutcomePatient Outcomes AssessmentsPatientsPelvisPersonal SatisfactionPhenotypePhysical activityPilot ProjectsPituitary GlandPlacebo ControlPlacebosPrevalencePrior ChemotherapyProductivityProstateQuality of lifeRadiation therapyRandomizedRandomized Controlled TrialsRecording of previous eventsReference ValuesReportingResearchRoleSafetySex BehaviorSex FunctioningSexual DysfunctionSupervisionSymptomsTestosteroneTherapeuticUnited Statesactive methodcancer therapychemotherapycomparative efficacydisabling symptomdouble-blind placebo controlled trialefficacy evaluationexperienceimprovedlean body massmalemembermenmuscle strengtholder menpatient populationpopulation basedprimary outcomerandomized placebo controlled trialreduce symptomsreduced muscle strengthside effecttestosterone replacement therapyyoung cancer survivoryoung man
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
The overall goal of this proposal is to evaluate the efficacy of testosterone replacement therapy in improving
fatigue and other outcomes such as sexual function, quality of life, body composition, muscle strength and
physical activity in a double-blind, randomized, placebo-controlled trial in young cancer survivors who report
fatigue and have testosterone deficiency. Fatigue is one of the most prevalent and debilitating symptoms in
men with cancer affecting 70-100% of patients irrespective of their age. Cancer-related fatigue is experienced
by patients not only during active cancer treatment, but is also highly prevalent in cancer survivors who exhibit
persistent fatigue months to years after the end of their treatment with the highest prevalence being in
recipients of chemotherapy and/or radiation therapy. In addition to fatigue, sexual dysfunction is also
highly prevalent in male cancer survivors. Male cancer survivors also have increased fat mass and
decreased lean body mass, a phenotype that predisposes them to reduced muscle strength. This phenotype
of fatigue, sexual dysfunction and adverse body composition is commonly encountered in non-cancer patient
populations with testosterone deficiency, a condition which is also highly prevalent (50-90%) in cancer
survivors. Pivotal trials of testosterone replacement therapy in non-cancer patient populations have shown an
improvement in fatigue, sexual function and body composition in men randomized to testosterone compared
with placebo. However, the efficacy of testosterone replacement therapy on cancer-related fatigue has not
been studied. We propose a large, 9-month, double-blind, randomized, placebo-controlled trial in which: 1) we
will compare the efficacy of weekly testosterone injections versus placebo in improving fatigue scores in cancer
survivors who report fatigue and also have testosterone deficiency, 2) we will compare the effects of
testosterone replacement versus placebo on sexual function, well-being, mood and quality of life, and 3) we
will determine the effect of testosterone administration on body composition, muscle strength and physical
activity compared with placebo. With an increase in longevity among cancer survivors and the growing
recognition of the importance of symptom control in the lives of these patients, the proposed trial is likely to
have a significant clinical impact in the management of patient-reported outcomes. If testosterone therapy is
found to be efficacious in alleviating these symptoms, the clinicians will have available to them a therapeutic
option that is relatively inexpensive, convenient to use and has a good safety record in young men.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging
-
批准号:10469444
-
项目类别:
-
资助金额:$19.23万
-
财政年份:2021
-
负责人:Shehzad Basaria
-
依托单位:
Exploring the Role of Testosterone as a Novel Anti-Nociceptive Agent in Women with Chronic Pain and Opioid Use
-
批准号:10413965
-
项目类别:
-
资助金额:$22.38万
-
财政年份:2021
-
负责人:Shehzad Basaria
-
依托单位:
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging
-
批准号:10300180
-
项目类别:
-
资助金额:$18.48万
-
财政年份:2021
-
负责人:Shehzad Basaria
-
依托单位:
Exploring the Role of Testosterone as a Novel Anti-Nociceptive Agent in Women with Chronic Pain and Opioid Use
-
批准号:10189910
-
项目类别:
-
资助金额:$26.85万
-
财政年份:2021
-
负责人:Shehzad Basaria
-
依托单位:
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging
-
批准号:10652585
-
项目类别:
-
资助金额:$18.91万
-
财政年份:2021
-
负责人:Shehzad Basaria
-
依托单位:
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism
-
批准号:10266840
-
项目类别:
-
资助金额:$71.3万
-
财政年份:2020
-
负责人:Shehzad Basaria
-
依托单位:
Preventing a Decline in Physical Function in Older Androgen-Deprived Men with Structured Exercise Training
-
批准号:10090555
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2020
-
负责人:Shehzad Basaria
-
依托单位:
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism
-
批准号:10118343
-
项目类别:
-
资助金额:$75.28万
-
财政年份:2020
-
负责人:Shehzad Basaria
-
依托单位:
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism
-
批准号:10426373
-
项目类别:
-
资助金额:$80.85万
-
财政年份:2020
-
负责人:Shehzad Basaria
-
依托单位:
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency
-
批准号:9982751
-
项目类别:
-
资助金额:$67.98万
-
财政年份:2019
-
负责人:Shehzad Basaria
-
依托单位:
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency
-
批准号:9816135
-
项目类别:
-
资助金额:$70.85万
-
财政年份:2019
-
负责人:Shehzad Basaria
-
依托单位:
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency
-
批准号:10212212
-
项目类别:
-
资助金额:$67.36万
-
财政年份:2019
-
负责人:Shehzad Basaria
-
依托单位:
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer
-
批准号:10617171
-
项目类别:
-
资助金额:$12.52万
-
财政年份:2019
-
负责人:Shehzad Basaria
-
依托单位:
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency
-
批准号:10403600
-
项目类别:
-
资助金额:$67.37万
-
财政年份:2019
-
负责人:Shehzad Basaria
-
依托单位:
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer
-
批准号:9927605
-
项目类别:
-
资助金额:$66.37万
-
财政年份:2019
-
负责人:Shehzad Basaria
-
依托单位:
Hypogonadism and Pain Perception in Androgen-Deprived Men with Prostate Cancer
-
批准号:8511920
-
项目类别:
-
资助金额:$24.39万
-
财政年份:2013
-
负责人:Shehzad Basaria
-
依托单位:
Hypogonadism and Pain Perception in Androgen-Deprived Men with Prostate Cancer
-
批准号:8639503
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2013
-
负责人:Shehzad Basaria
-
依托单位:
ISOFLAVONES IN PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY
-
批准号:7604633
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2006
-
负责人:Shehzad Basaria
-
依托单位:
ISOFLAVONES IN PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY
-
批准号:7378920
-
项目类别:
-
资助金额:$0.07万
-
财政年份:2005
-
负责人:Shehzad Basaria
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: